Presentation of Kancera’s Interim Report for the fourth quarter 2023

Presentation of the statistical analyses of the FRACTAL top line results

CEO Peter Selin presents Kancera’s Q3 2023 Interim Report

CEO Peter Selin presents KANDOVA, Kancera’s ongoing clinical study in ovarian cancer